Skip to main content
. 2022 Nov 9;18(8):1818–1826. doi: 10.4103/1673-5374.360242

Figure 7.

Figure 7

Effects of exendin-4 and linagliptin on the NLRP3/caspase-1/IL-1β pathway in the SN of Parkinson’s disease mice.

(A) Representative western blot image of NLRP3, pro-IL-1β, mature IL-1β, and cleaved caspase-1 expression in the SN. (B–E) Quantification of NLRP3, cleaved caspase-1, pro-IL-1β, and mature IL-1β protein expression levels. Data are shown as mean ± SD (n = 3). *P < 0.05, **P < 0.01, vs. CON; #P < 0.05, ##P < 0.01, vs. MPTP (one-way analysis of variance followed by Tukey’s post hoc test). CON: Control; EX-4: exendin-4; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; IL-1β: interleukin-1β; LINA: linagliptin; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NLRP3: nucleotide-binding oligomerization domain- and leucine-rich-repeat- and pyrin-domain-containing 3; SN: substantia nigra.